» Articles » PMID: 38721006

Critical Roles and Clinical Perspectives of RNA Methylation in Cancer

Overview
Journal MedComm (2020)
Specialty Health Services
Date 2024 May 9
PMID 38721006
Authors
Affiliations
Soon will be listed here.
Abstract

RNA modification, especially RNA methylation, is a critical posttranscriptional process influencing cellular functions and disease progression, accounting for over 60% of all RNA modifications. It plays a significant role in RNA metabolism, affecting RNA processing, stability, and translation, thereby modulating gene expression and cell functions essential for proliferation, survival, and metastasis. Increasing studies have revealed the disruption in RNA metabolism mediated by RNA methylation has been implicated in various aspects of cancer progression, particularly in metabolic reprogramming and immunity. This disruption of RNA methylation has profound implications for tumor growth, metastasis, and therapy response. Herein, we elucidate the fundamental characteristics of RNA methylation and their impact on RNA metabolism and gene expression. We highlight the intricate relationship between RNA methylation, cancer metabolic reprogramming, and immunity, using the well-characterized phenomenon of cancer metabolic reprogramming as a framework to discuss RNA methylation's specific roles and mechanisms in cancer progression. Furthermore, we explore the potential of targeting RNA methylation regulators as a novel approach for cancer therapy. By underscoring the complex mechanisms by which RNA methylation contributes to cancer progression, this review provides a foundation for developing new prognostic markers and therapeutic strategies aimed at modulating RNA methylation in cancer treatment.

Citing Articles

Notch signaling in the tumor immune microenvironment of colorectal cancer: mechanisms and therapeutic opportunities.

Sun J, Chen Y, Xu Z, Wang W, Li P J Transl Med. 2025; 23(1):315.

PMID: 40075484 PMC: 11900264. DOI: 10.1186/s12967-025-06282-z.


Implication of protein post translational modifications in gastric cancer.

Song H, Zhang M, Guo C, Guo X, Ma Y, Ma Y Front Cell Dev Biol. 2025; 13:1523958.

PMID: 39968176 PMC: 11833226. DOI: 10.3389/fcell.2025.1523958.


Exploring m6A modifications in gastric cancer: from molecular mechanisms to clinical applications.

Li P, Fang X, Huang D Eur J Med Res. 2025; 30(1):98.

PMID: 39940056 PMC: 11823136. DOI: 10.1186/s40001-025-02353-5.


ALKBH5 suppresses gastric cancer tumorigenesis and metastasis by inhibiting the translation of uncapped WRAP53 RNA isoforms in an m6A-dependent manner.

Zheng Z, Lin F, Zhao B, Chen G, Wei C, Chen X Mol Cancer. 2025; 24(1):19.

PMID: 39815301 PMC: 11734446. DOI: 10.1186/s12943-024-02223-4.


Targeting the JAK-STAT pathway in colorectal cancer: mechanisms, clinical implications, and therapeutic potential.

Li P, Huang D Front Cell Dev Biol. 2024; 12:1507621.

PMID: 39659524 PMC: 11628519. DOI: 10.3389/fcell.2024.1507621.


References
1.
Huang H, Wang Y, Kandpal M, Zhao G, Cardenas H, Ji Y . FTO-Dependent -Methyladenosine Modifications Inhibit Ovarian Cancer Stem Cell Self-Renewal by Blocking cAMP Signaling. Cancer Res. 2020; 80(16):3200-3214. PMC: 7442742. DOI: 10.1158/0008-5472.CAN-19-4044. View

2.
Cadoret A, Ovejero C, Terris B, Souil E, Levy L, Lamers W . New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene. 2002; 21(54):8293-301. DOI: 10.1038/sj.onc.1206118. View

3.
Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View

4.
Choudhary C, Weinert B, Nishida Y, Verdin E, Mann M . The growing landscape of lysine acetylation links metabolism and cell signalling. Nat Rev Mol Cell Biol. 2014; 15(8):536-50. DOI: 10.1038/nrm3841. View

5.
Harvey Z, Chen Y, Jarosz D . Protein-Based Inheritance: Epigenetics beyond the Chromosome. Mol Cell. 2017; 69(2):195-202. PMC: 5775936. DOI: 10.1016/j.molcel.2017.10.030. View